A PET probe that detects the amino acid glutamine predicts whether tumors respond to certain targeted therapies in preclinical animal models.

Vanderbilt researchers have discovered that activation of a certain signaling pathway protects brain cancers from targeted therapies, suggesting that using therapeutics that block both pathways may be a promising treatment.

Biomarker tests that help determine which patients may benefit from molecularly targeted therapies need better evidence and oversight to improve their effectiveness and availability, according to a study by the Institute of Medicine (IOM) of the National Academies of Sciences, Engineering, and Medicine.

Vanderbilt investigators have discovered a way to overcome the resistance of some lung cancers to certain targeted therapies, which could lead to more effective treatments for lung cancer patients.

Vanderbilt researchers have identified a new target for blocking breast cancer metastasis.

Vanderbilt investigators have constructed a network map that could guide the development of new targeted cancer therapies.

The protein MTBP is overexpressed in an aggressive type of breast cancer, and it regulates another protein implicated in many cancer types, suggesting that it may be a good target for new therapeutics.